Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16745735 | 0.82 | THRB (0.55) | THRBLMNAPOLBKMT2AHDAC1 | |
| SCHEMBL2824188 | 0.81 | GLS (0.48) | THRBLMNAPOLBKMT2ATDP1 | |
| SCHEMBL1178459 | 0.79 | LMNA (0.45) | THRBLMNAPOLBKMT2ATDP1 | |
| SCHEMBL12890290 | 0.78 | THRB (0.51) | THRBLMNAPOLBKMT2AMAPT | |
| SCHEMBL4663218 | 0.77 | EGLN3 (0.50) | THRBLMNAPOLBKMT2AFDPS | |
| SCHEMBL16748551 | 0.77 | THRB (0.47) | THRBLMNAPOLBKMT2ATDP1 | |
| SCHEMBL24930971 | 0.76 | THRB (0.44) | THRBLMNAPOLBKMT2AMAPT | |
| Hydrochloric Acid SCHEMBL17337686 | 0.76 | EGLN3 (0.48) | THRBLMNAPOLBKMT2AFDPS | |
| SCHEMBL412090 | 0.76 | THRB (0.48) | THRBLMNAPOLBKMT2AHDAC1 | |
| SCHEMBL14578736 | 0.75 | THRB (0.51) | THRBLMNAPOLBKMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413274-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210046045-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-02-18 | — | — | US | disclosed |
| US-10736875-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180369197-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-12-27 | — | — | US | disclosed |
| US-10111859-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2780322-B1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | LIGAND PHARM INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20160374989-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9492430-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140296292-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2014-10-02 | — | — | US | disclosed |
| EP-2780322-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | Ligand Pharmaceuticals Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013074459-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | LIGAND PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369197-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | THRB 1986/4885LMNA 4275/4885POLB 2612/4885 |
| US-20160374989-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | THRB 1986/4885LMNA 4275/4885POLB 2612/4885 |
| US-20140296292-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | THRB 1986/4885LMNA 4275/4885POLB 2612/4885 |
| US-11413274-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | THRB 1986/4885LMNA 4275/4885POLB 2612/4885 |
| US-10111859-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | THRB 1986/4885LMNA 4275/4885POLB 2612/4885 |
| US-20210046045-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | THRB 1986/4885LMNA 4275/4885POLB 2612/4885 |
| US-10736875-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | THRB 1986/4885LMNA 4275/4885POLB 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.